血清M2BPGi可靠地评估慢性乙型肝炎肝纤维化

StephenW

Hannah Dellabella
July 31, 2018
Serum M2BPGi Reliably Assesses Liver Fibrosis in Chronic Hepatitis B

Serum M2BPGi is a reliable marker for assessing liver fibrosis in patients with chronic hepatitis B virus infection. Serum M2BPGi is a reliable marker for assessing liver fibrosis in patients with chronic hepatitis B virus infection.

For patients with chronic hepatitis B virus infection (CHB), serum mac-2-binding protein glycosylation isomer (M2BPGi) is a reliable marker for assessing liver fibrosis, according to results published in Clinical and Translational Gastroenterology.

M2BPGi presents a noninvasive alternative to the standard invasive liver biopsy for assessing liver fibrosis in CHB. Furthermore, M2BPGi appears to correlate well with histologic stages of liver fibrosis.

The study included participants with CBH treated with nucleos(t)ide analogues with baseline liver biopsies and retrievable serum samples (n=327). The researchers performed paired liver biopsies at 1 and 3 years.

The median M2BPGi values increased progressively with more advanced stages of liver fibrosis. The median M2BPGi was 0.26 in liver histology with Ishak F0-1, 0.34 for F2, 0.57 for F3, and 1.21 for F4 (P <.01).

The area under the receiver operator curve for serum M2BPGi was 0.653 for diagnosing ≥F2, (95% CI, 0.608-0.698, P <.001), 0.795 for diagnosing ≥F3 (95% CI, 0.743-0.848; P <.001), and 0.914 for diagnosing F4 (95% CI, 0.815-1.00, P <.001).

The researchers found that the optimal serum M2BPGi cutoff values for diagnosing ≥F2, ≥F3, and F4 were 0.25, 0.45, and 0.96, respectively.


After multivariate analysis, the researchers found that MSBPGi was the most significant independent factor for ≥F3 compared with aspartate aminotransferase to platelet ratio, aspartate aminotransferase to alanine aminotransferase ratio, and fibrosis index based on 4 factors (odds ratio, 8.197; 95% CI, 2.699-24.897; P <.001).

“Serum M2BPGi is a potential marker to conveniently diagnose F3/F4 without needing a liver biopsy,” the study authors concluded.
Reference

Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gasteroenterol. 2018;9(6):163[CM1].

StephenW

汉娜德拉贝拉
2018年7月31日
血清M2BPGi可靠地评估慢性乙型肝炎肝纤维化

血清M2BPGi是评估慢性乙型肝炎病毒感染患者肝纤维化的可靠标志物。血清M2BPGi是评估慢性乙型肝炎病毒感染患者肝纤维化的可靠标志物。

根据临床和转化胃肠病学发表的结果，对于慢性乙型肝炎病毒感染（CHB）患者，血清mac-2结合蛋白糖基化异构体（M2BPGi）是评估肝纤维化的可靠标志物。

M2BPGi提供了一种非侵入性替代标准侵入性肝活检，用于评估CHB中的肝纤维化。此外，M2BPGi似乎与肝纤维化的组织学阶段很好地相关。

该研究包括用核苷（t）ide类似物治疗的CBH参与者，其具有基线肝脏活组织检查和可回收的血清样品（n = 327）。研究人员在1年和3年时进行了配对肝脏活组织检查。

中位M2BPGi值随肝纤维化的晚期阶段逐渐增加。肝脏组织学中M2BPGi中位数为0.26，Ishak F0-1，F2为0.34，F3为0.57，F4为1.21（P <.01）。

血清M2BPGi接受者操作曲线下面积为0.653，诊断≥F2，（95％CI，0.608-0.698，P <.001），诊断≥F3为0.795（95％CI，0.743-0.848; P <.001 ）和0.914用于诊断F4（95％CI，0.815-1.00，P <.001）。

研究人员发现，诊断≥F2，≥F3和F4的最佳血清M2BPGi截断值分别为0.25,0.45和0.96。


多变量分析后，研究人员发现MSBPGi是≥F3最显着的独立因子，与天冬氨酸氨基转移酶与血小板比例，天冬氨酸氨基转移酶与丙氨酸氨基转移酶比率以及基于4因子的纤维化指数相比（优势比，8.197; 95％CI， 2.699-24.897; P <.001）。

研究作者总结道，“血清M2BPGi是一种可以方便地诊断F3 / F4而无需肝活检的潜在标志物”。
参考

Mak LY，Wong DK，Cheung KS，Seto WK，Lai CL，Yuen MF。血清M2BPGi水平对慢性乙型肝炎病毒感染患者显着肝纤维化和肝硬化的诊断价值。 Clin Transl Gasteroenterol。 2018; 9（6）：163 [CM1]。